Phase I Study of [14C]Zorifertinib Shows Promising Safety and Pharmacokinetics
[14C]Zorifertinib is undergoing Phase I study to evaluate its safety and pharmacokinetics in healthy males.
Phase I
Oncology / Small Molecule
Status
Active
Sponsor
Alpha Biopharma
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase I study of [14C]Zorifertinib is critical as it assesses safety and pharmacokinetics, which are essential for advancing the drug's development in oncology. Positive outcomes could significantly bolster Alpha Biopharma's competitive position in the oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results from the study, particularly safety data and pharmacokinetic profiles, as they may influence further clinical development.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.